Sign in

    West Pharmaceutical Services Inc (WST)

    Board Change

    You might also like

    Business Description

    WST is a leading global manufacturer specializing in the design and production of advanced, high-quality containment and delivery systems for injectable drugs and healthcare products. The company operates through two main segments: Proprietary Products and Contract-Manufactured Products, catering to biologic, generic, and pharmaceutical drug customers . WST's product portfolio includes proprietary packaging, containment solutions, drug delivery systems, and custom contract-manufacturing and assembly solutions . The company emphasizes its global reach, with operations in North America, Europe, Asia, and South America, aligning with its multinational customer base .

    1. Proprietary Products - Offers proprietary packaging, containment solutions, and drug delivery systems, including stoppers, seals, syringe and cartridge components, and self-injection devices, primarily serving biologic, generic, and pharmaceutical drug customers.
    2. Contract-Manufactured Products - Focuses on the design, manufacture, and automated assembly of complex devices for pharmaceutical, diagnostic, and medical device customers, providing custom contract-manufacturing and assembly solutions such as multi-component molding and clean room molding.

    Key Metrics

    View all financials →

    Executive Team

    NamePositionStart DateShort Bio
    Silji AbrahamSenior Vice President, Chief Technology OfficerDecember 2020Silji Abraham has been serving as the Senior Vice President and Chief Technology Officer since December 2020. Previously, he was the Senior Vice President, Chief Digital and Transformation Officer from February 2018 to December 2020 .
    Bernard J. BirkettSenior Vice President and Chief Financial and Operations OfficerJuly 2022Bernard J. Birkett has been serving as the Senior Vice President and Chief Financial and Operations Officer since July 2022. He joined the company as Senior Vice President and Chief Financial Officer in June 2018 .
    Annette F. FavoriteSenior Vice President and Chief Human Resources OfficerOctober 2015Annette F. Favorite has been the Senior Vice President and Chief Human Resources Officer since October 2015. She previously spent over 25 years at IBM Corporation in various strategic and global human resources roles .
    Eric M. GreenPresident, Chief Executive Officer, and Chair of the BoardApril 2015Eric M. Green has been serving as the President and Chief Executive Officer since April 2015 and as the Chair of the Board since May 2022. He previously held senior roles at Sigma-Aldrich Corporation .
    Quintin J. LaiVice President, Strategy and Investor RelationsJanuary 2016Quintin J. Lai has been serving as the Vice President, Strategy and Investor Relations since January 2016. He also handled Corporate Development responsibilities from January 2016 to September 2021 .
    Kimberly Banks MacKaySenior Vice President, General Counsel, and Corporate SecretaryDecember 2020Kimberly Banks MacKay has been serving as the Senior Vice President, General Counsel, and Corporate Secretary since December 2020. She previously held a similar role at the Segal Group in New York .
    Cindy Reiss-ClarkChief Commercial OfficerMay 2022Cindy Reiss-Clark has been the Chief Commercial Officer since May 2022. She previously served as Senior Vice President, Global Markets and Commercial Solutions from November 2019 .
    Chad R. WintersVice President, Chief Accounting Officer and Corporate ControllerMay 2020Chad R. Winters has been serving as the Vice President, Chief Accounting Officer and Corporate Controller since May 2020. He initially joined the company as Vice President and Corporate Controller in October 2019 .
    John Sweeney, CFAVice President, Investor RelationsN/AJohn Sweeney, CFA, serves as the Vice President of Investor Relations. He was present at the Stephens Conference in November 2024, representing the company in his role .
    Michele PolinskyVice President, Global CommunicationsN/AMichele Polinsky is mentioned as the Vice President of Global Communications, but specific details on her start date or a detailed biography are not provided .

    Questions to Ask Management

    1. You mentioned seeing signs of stabilization and customers showing interest in increasing near-term orders, yet destocking with some generic customers is expected to continue into 2025; can you elaborate on the factors driving this continued destocking and how it affects your overall growth outlook?

    2. Given that some of the strong Q3 performance was attributed to customers accelerating orders ahead of schedule, how confident are you that this demand pull-forward won't create a shortfall in future quarters, and what measures are you taking to sustain growth?

    3. With the significant sequential increase in Contract Manufacturing gross margins driven by scaling capacity and new capabilities, what specific strategies are in place to ensure this margin improvement is sustainable, and how do you see this segment contributing to overall profitability?

    4. Considering your plans to reduce CapEx to more normalized levels over the next 12 to 24 months while continuing to invest in growth areas, how will this impact your ability to meet increasing demand in high-growth segments like biologics and GLP-1 drugs?

    5. Despite a strong third quarter, you've narrowed your organic growth guidance toward the lower end of the range; are there emerging challenges or shifts in the market that influenced this adjustment, and can you provide more detail on the assumptions behind your guidance for Q4?

    Share Repurchase Program

    Program DetailsProgram 1
    Approval DateFebruary 2023
    End Date/DurationNo expiration date
    Total additional amount$1.0 billion
    Remaining authorization amount$55.2 million (as of September 30, 2024)
    DetailsProvides flexibility for incremental share repurchases, maintains a share count-neutral strategy, and potentially enhances shareholder value by returning capital to shareholders.

    Auditor

    NameStart DateEnd DateReason for Change
    PricewaterhouseCoopers LLP1963 PresentCurrent auditor

    Latest news

    Recent developments and announcements about WST.

    Corporate Leadership

      Board Change

      ·
      Dec 11, 2024, 9:40 PM

      Janet Haugen has been elected to the Board of Directors of West Pharmaceutical Services, Inc. as of December 9, 2024. With her addition, the Board now consists of 12 directors. Ms. Haugen, aged 66, is the former Chief Financial Officer of Unisys Corporation and will participate on the Audit Committee of the Board .